Form 4: Oramed COO & CBO Hexter Acquires 19,000 Shares

Oramed Pharmaceuticals' COO and CBO, Joshua Hexter, acquired 19,000 shares of common stock through the vesting of performance stock units.

Summary

• Joshua Hexter, the Chief Operating Officer and Chief Business Officer of ORAMED PHARMACEUTICALS INC. (ORMP), reported a change in his beneficial ownership of company securities.
• On January 22, 2026, Hexter acquired 19,000 shares of Oramed Common Stock.
• These shares were received for no consideration upon the vesting of performance stock units (PSUs) that were granted on December 31, 2025.
• The vesting occurred because Oramed's common stock achieved a specified price per share.
• Following this transaction, Hexter beneficially owns a total of 1,064,495 shares of Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the vesting of performance stock units implies the achievement of a stock price target, and it increases insider ownership, which can align management interests with shareholders.

Positives

• The vesting of 19,000 performance stock units indicates that the company's common stock achieved a specified price per share, suggesting positive stock performance relative to internal targets.
• Increased insider ownership by a key executive (COO & CBO) can signal confidence in the company's future prospects and aligns management's interests with shareholders.

Negatives

• No negative information is typically disclosed in a Form 4 filing, which solely reports insider transactions.

Risks

• This Form 4 filing does not contain information regarding company-specific risks.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, such as the vesting of performance stock units, are often viewed by investors as an indicator of management's confidence in the company's future. While this specific transaction is a pre-planned equity compensation event, the underlying condition of achieving a 'specified price per share' suggests positive stock performance relative to internal targets, which could be a positive signal for Oramed Pharmaceuticals within the biotechnology and pharmaceutical industry.

Stakeholder Impact

• Shareholders: Potentially positive signal due to the achievement of a stock price target and increased insider ownership, which can foster confidence.
• Employees: The vesting of PSUs is part of executive compensation, which can motivate performance and align executive incentives with company success.

Key Dates

Keywords

Oramed Pharmaceuticals, ORMP, Joshua Hexter, Insider Transaction, Form 4, Performance Stock Units, Equity Compensation, Beneficial Ownership